Tuesday, October nineteenth @ 8:00 am Jap Time
WARRINGTON, Pa., Oct. 14, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical gadget firm centered on advancing a number of late-stage interventions for acute cardiovascular and pulmonary issues, right now introduced that on Tuesday, October 19, 2021 at 8:00 am Jap Time it’ll host a Key Opinion Chief (KOL) webinar on istaroxime for the remedy of acute coronary heart failure and the upcoming information in early cardiogenic shock.
The webinar will characteristic a presentation by KOL John Teerlink, M.D., College of California-San Francisco, who will talk about the present remedy panorama and unmet medical want in treating sufferers with acute coronary heart failure and the potential position for istaroxime, the corporate’s product candidate, a first-in-class, twin motion, agent in medical improvement for the remedy of acute decompensated coronary heart failure (ADHF).
Windtree’s administration group will even talk about the medical improvement program for istaroxime, which has been studied in two Part 2 medical trials up to now. Moreover, Windtree will talk about its improvement program for istaroxime in early cardiogenic shock, which is presently in a Part 2 examine with focused completion in This autumn 2021.
A dwell Q&A session will observe the formal displays.
To register for the occasion, please click on here.
Dr. John R. Teerlink, F.A.C.C., F.A.H.A., F.E.S.C., F.H.F.A., F.H.F.S.A., F.R.C.P.(UK) is Director of Coronary heart Failure and of the Echocardiography Laboratory on the San Francisco Veterans Affairs Medical Middle in San Francisco, California. He’s actively concerned within the design and execution of many acute and persistent coronary heart failure medical trials, serving on endpoint, information security monitoring, and steering committees for quite a few worldwide research investigating a wide range of new therapies. He serves as a marketing consultant on medical improvement packages in a number of areas of cardiology, in addition to in cardiovascular security for non-cardiovascular indications. Dr. Teerlink accomplished a four-year time period as a everlasting member of the FDA Cardiovascular and Renal Medication Advisory Committee, and ceaselessly serves as an advert hoc member of a number of different FDA advisory committees and panels for medical gadgets, diagnostics, biologics, and medicines. He’s a member of the joint FDA/Duke College Standardized Information Assortment for Cardiovascular Medical Trials Initiative to develop standardized definitions for cardiovascular endpoints. Dr. Teerlink is an lively member of the Coronary heart Failure Society of America, serving on many committees together with the Membership, Scientific Program, Company Affairs, Growth, Lifetime Achievement Award and Guideline Committees, and presently serves as Secretary and on the Board of Administrators and the Govt Council. He additionally presently serves on the Acute Coronary heart Failure Committee of the European Society of Cardiology Coronary heart Failure Affiliation and has served on the Nationwide Committee on Coronary heart Failure and Transplantation of the American Coronary heart Affiliation. He’s a founding and constitution member of the American Affiliation of Coronary heart Failure Nurses. He obtained his medical diploma from Harvard Medical College, the place he carried out a 12 months of analysis within the laboratory of Drs. Janice and Marc Pfeffer, and accomplished an inside drugs residency on the College of California San Francisco (UCSF). He continued his fundamental science coaching by means of a post-doctoral analysis fellowship at Hoffman-LaRoche in Basel, Switzerland with Drs. Martine and Jean-Paul Clozel. Dr. Teerlink accomplished his cardiovascular drugs fellowship and a Howard Hughes post-doctoral analysis fellowship at UCSF, subsequently becoming a member of the school, the place he presently is a Professor of Medical Medication.
About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing a number of late-stage interventions for acute cardiovascular and acute pulmonary issues to deal with sufferers in moments of disaster. Utilizing new scientific and medical approaches, Windtree is creating a multi-asset franchise anchored round compounds with a capability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class remedy for acute coronary heart failure and for early cardiogenic shock. Windtree’s coronary heart failure platform consists of follow-on oral pre-clinical SERCA2a activator property as effectively. In pulmonary care, Windtree has centered on creating AEROSURF®, a drug-device mixture, to ship its artificial KL4 surfactant non-invasively to untimely infants with respiratory misery syndrome, and is facilitating switch of medical improvement of AEROSURF® to its licensee in Asia, Lee’s HK. Windtree can also be evaluating KL4 surfactant for the remedy of acute respiratory misery syndrome in COVID-19 sufferers. Additionally in Windtree’s portfolio is rostafuroxin, a novel precision drug product focusing on hypertensive sufferers with sure genetic profiles.
For extra info, please go to the Firm’s web site at www.windtreetx.com.
212.915.3820 or email@example.com
646.876.5868 or firstname.lastname@example.org